Plain-English translation of NCT07466212 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study follows cancer patients receiving immune checkpoint inhibitor (ICI) immunotherapy to understand how the treatment affects their quality of life and well-being. The researchers want to compare how patients with type 2 diabetes experience this treatment versus patients without diabetes, since diabetes may make side effects or overall well-being more challenging during this medication.
While the medication has transformed cancer care, it can cause side effects that affect many body systems, and diabetes may make these effects worse or harder to manage. Researchers don't yet know whether patients with diabetes experience different quality-of-life changes during this treatment compared to those without diabetes, so this study aims to fill that knowledge gap.
You likely qualify if…
You likely don't qualify if…
You will continue receiving your planned immunotherapy as normal while completing quality-of-life questionnaires at baseline, 3 months, and 6 months after starting treatment. The study does not involve additional medications or procedures—it focuses on collecting your responses about how you're feeling and managing your health during this time. You'll be asked to track and share your experiences through surveys designed to capture how the treatment affects your daily life and well-being.
AI-generated summary from trial data · Oct 23, 2026 · Not medical advice
Denmark